摘要BackgroundPolymer coating on coronary stents induces vascular inflammatory response,reduces re-endothelialization,and affects long-term outcome after percutaneous coronary intervention (PCI).The SERY-1 registry aimed to determine whether a novel polymer-free paclitaxel-eluting microporous Yinyi stent could improve 1-year outcome after index procedure in real-world clinical practice.Methods Clinical and angiographic data and follow-up outcome were collected in 1045 patients who underwent PCI with implantation of ≥1 Yinyi stents between June 2008 and August 2009 at 27 medical centers.The primary endpoint was the cumulative rate of composite major adverse cardiac events (MACE) and the secondary endpoint was the incidence of stent thrombosis at 1 year.Results Overall,1376 lesions were treated successfully with 1713 Yinyi stents,and 1019 (98.7％) patients received dual antiplatelet therapy for at least 12 months.During 1-year follow-up,8 patients (0.78％) had cardiac death,6 (0.58％)suffered non-fatal myocardial infarction,and 46 (4.46％) underwent repeat PCI due to recurrence of angina,resulting in 1-year MACE-free survival of 94.09％.Stent thrombosis occurred in 10 (0.97％) patients,and the rate of Academic Research Consortium (ARC) definite or probable stent thrombosis was 0.78％.Conclusions Polymer-free paclitaxel-eluting microporous Yinyi stent is effective and safe for interventional treatment of coronary artery disease in real-world clinical practice,without recourse to carrier polymer.Potential long-term clinical advantages of this stent deserve further investigation.